文献速递胸部肿瘤放疗放疗物理与技术

大肿瘤(≥5 cm)非小细胞肺癌立体定向放疗中分次方案与肿瘤位置对毒性的影响:多中心分析

Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-12-02

PURPOSE: To describe the impact of fractionation scheme and tumor location on toxicities in stereotactic body radiation therapy (SBRT) for ≥5-cm non-small cell lung cancer (NSCLC), as part of a multi-institutional analysis.…

要点

  • 每日SBRT组≥2级毒性发生率为43%,隔日/非每日方案组为7%,差异显著(P<.001)。
  • 每日治疗组≥2级肺毒性发生率也更高(P=.014)。
  • 中央型与周围型肿瘤的≥2级毒性无显著差异(P>.05)。

核心结论

  • 对于≥5 cm的非小细胞肺癌,SBRT毒性可接受,但每日治疗与更高的毒性发生率相关。

主要发现

  • 全组≥2级和≥3级毒性发生率分别为25%和7%。
  • 每日治疗组(n=46)≥2级毒性发生率为43%,隔日/非每日组(n=46)为7%,差异显著(P<.001)。
  • 每日治疗组≥2级肺毒性发生率更高(P=.014)。
  • 周围型肿瘤(n=66)比中央型肿瘤(n=26)更常接受3/4次分割方案。
  • 按肿瘤位置分层,≥2级毒性无显著差异(P>.05)。

关键数值与推荐

  • 每日治疗组≥2级毒性43% vs 隔日/非每日组7%(P<.001)。
  • ≥2级肺毒性:每日组 vs 隔日/非每日组差异有统计学意义(P=.014)。
  • ≥3级毒性发生率7%,≥2级毒性发生率25%。
  • 1例每日治疗患者发生5级放射性肺炎。

临床怎么用

  • 对于≥5 cm的非小细胞肺癌行SBRT时,可优先考虑隔日或非每日分割方案以降低毒性风险。

局限性

  • 中位随访仅12个月,可能低估晚期毒性。
  • 隔日/非每日组更常采用3/4次分割方案,分次方案与治疗间隔的影响可能混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the impact of fractionation scheme and tumor location on toxicities in stereotactic body radiation therapy (SBRT) for ≥5-cm non-small cell lung cancer (NSCLC), as part of a multi-institutional analysis. METHODS: Patients with primary ≥5-cm N0 M0 NSCLC who underwent ≤5-fraction SBRT were examined across multiple high-volume SBRT centers. Collected data included clinical/treatment parameters; toxicities were prospectively assessed at each institution according to the Common Terminology Criteria for Adverse Events. Patients treated daily were compared with those treated every other day (QOD)/other nondaily regimens. Stratification between central and peripheral tumors was also performed. RESULTS: Ninety-two patients from 12 institutions were evaluated (2004-2016), with median follow-up of 12 months. In total there were 23 (25%) and 6 (7%) grade ≥2 and grade ≥3 toxicities, respectively. Grades 2 and 3 pulmonary toxicities occurred in 9% and 4%, respectively; 1 patient treated daily experienced grade 5 radiation pneumonitis. Of the entire cohort, 46 patients underwent daily SBRT, and 46 received QOD (n=40)/other nondaily (n=6) regimens. Clinical/treatment parameters were similar between groups; the QOD/other group was more likely to receive 3-/4-fraction schemas. Patients treated QOD/other experienced significantly fewer grade ≥2 toxicities as compared with daily treatment (7% vs 43%, P<.001). Patients treated daily also had higher rates of grade ≥2 pulmonary toxicities (P=.014). Patients with peripheral tumors (n=66) were more likely to receive 3-/4-fraction regimens than those with central tumors (n=26). No significant differences in grade ≥2 toxicities were identified according to tumor location (P>.05). CONCLUSIONS: From this multi-institutional study, toxicity of SBRT for ≥5-cm lesions is acceptable, and daily treatment was associated with a higher rate of toxicities.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Verma V, Shostrom VK, Zhen W, et al. Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis. Int J Radiat Oncol Biol Phys. 2016. PMID: 28244414. doi:10.1016/j.ijrobp.2016.11.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。